Form D · Biotechnology
Finch Therapeutics, Inc.
Somerville, MA · CIK 0001661704
Offering snapshot reported Jan 23, 2017 · SEC filing
- Reported sold
- $3.73M Offering amount: $3.75M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 28, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 23, 2017 | Initial | $3,734,177 | No comparison | 6 | SEC filing |
| Dec 29, 2015 | Initial | $800,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-278987
Series A Preferred
Source: Form D, filed Jan 23, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Alm | Promoter |
| James Burgess | Director, Promoter |
| Zain Kassam | Promoter |
| Andrew Noh | Director, Executive, Promoter |
| William Perkins | Executive |
| Mark Smith | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Inner Belt Road
Somerville, MA, 02143
Somerville, MA, 02143